What question did this study set out to answer?

The study aims to evaluate the cancer specificity of AG-270 in combination with recombinant methioninase (rMETase).

synapse

⌘+K

synapse

⌘+K

February 2, 2026

Lack of Cancer Specificity of Methionine Adenosyltransferase 2A (MAT2A) Inhibitor AG-270 in Combination With Recombinant Methioninase In Vitro.

Key Points

The study aims to evaluate the cancer specificity of AG-270 in combination with recombinant methioninase (rMETase).
Conducted in vitro tests on both cancer and normal cell lines.
Assessed the effects of AG-270 in combination with rMETase.
Compared AG-270's effects with traditional chemotherapy agents.
AG-270 demonstrated a lack of cancer specificity, affecting both cancerous and normal cells.
In contrast, traditional chemotherapy drugs showed synergistic effects specifically on cancer cells.
Findings indicate MAT2A inhibition impacts essential metabolic pathways in various cell types.

Abstract

AG-270 showed lack of cancer specificity in combination with rMETase when tested on both cancer and normal cells. The present results contrast with numerous chemotherapy agents, which in combination with rMETase are synergistic on cancer cells but not on normal cells. The present findings suggest that MAT2A inhibition affects crucial metabolic pathways in normal as well as cancer cell types and thus AG-270 may not be suitable as a cancer-specific therapeutic strategy.

Mark Helpful

Bookmark

Relay